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N
anoparticles (NPs) have shown great
promise in the rapidly evolving ﬁeld
of nanomedicine as nanocarriers for
drug delivery,1,2 for ﬂuorescence imaging,3,4
andas contrast agents formagnetic resonance
imaging (MRI).5 Indeed, NPs approved by
the Food and Drug Administration (FDA) are
currently in use for treatment of metastatic
adenocarcinoma of pancreas (Abraxane,
a protein-based carrier), ovarian cancer that
has progressed or recurred after platinum-
based chemotherapy (Doxil, a liposome-based
carrier), and for MRI of liver (Ferumoxide,
dextran-coated iron oxide NPs).2,6 In addition,
a polymeric micelle NP (Genexol-PM) was
approved in Korea and is in phase II clinical
development in the USA,2,6 while the ﬁrst
targeted poly(lactide-co-glycolide)-b-poly-
(ethylene glycol) (PLGAPEG) NPs have
successfully completed phase I clinical trials
and advanced to phase II clinical trials for
prostate cancer therapy.7
Despite these advances, translation of
NPs from the bench to bedside is diﬃcult;
among the major challenges is controlling
the properties and quality of NPs from
laboratory scale synthesis to the clinical
production scale.1 While NPs are conven-
tionally synthesized by batch type reactors,
these bulk synthesis methods tend to have
limited batch-to-batch reproducibility and
controllability in terms of physicochemical
properties of the synthesized NPs.8 In addi-
tion, the scaling up of batch procedures
for industrial-scaleproductionneeds consider-
able trial and error for process optimization.9
Because the in vivo fate of NPs strongly
depends on their physicochemical prop-
erties,1,2,7 methods to synthesize NPs in a
reproducible and controlled manner from
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ABSTRACT High-throughput production of nanoparticles (NPs) with controlled quality is
critical for their clinical translation into eﬀective nanomedicines for diagnostics and
therapeutics. Here we report a simple and versatile coaxial turbulent jet mixer that can
synthesize a variety of NPs at high throughput up to 3 kg/d, while maintaining the
advantages of homogeneity, reproducibility, and tunability that are normally accessible only
in specialized microscale mixing devices. The device fabrication does not require specialized
machining and is easy to operate. As one example, we show reproducible, high-throughput
formulation of siRNA-polyelectrolyte polyplex NPs that exhibit eﬀective gene knockdown but
exhibit signiﬁcant dependence on batch size when formulated using conventional methods.
The coaxial turbulent jet mixer can accelerate the development of nanomedicines by providing a robust and versatile platform for preparation of NPs at
throughputs suitable for in vivo studies, clinical trials, and industrial-scale production.
KEYWORDS: nanoparticles . mixer . turbulent jet . nanomedicine . nanoprecipitation . rapid mixing . large-scale . microﬂuidics
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laboratory-scale in vitro screening studies all theway to
production scale are critical for the development and
translation of NPs to the clinic.
Continuous synthesis of NPs typically provides bet-
ter reproducibility and controllability compared to
batch-type bulk synthesis methods.1012 Recently,
the ability of microﬂuidic platforms to oﬀer precisely
controlled reaction environments has been harnessed
to enhance the controllability and reproducibility of NP
synthesis.1,2,9,11,13 Controlled synthesis of NPs through
nanoprecipitation by rapid mixing in microﬂuidic plat-
forms has been shown to improve the homogeneity of
polymeric NPs.11,1421 Microﬂuidic platforms have also
been used for tuning the physicochemical properties
of NPs including size, surface chemistry, surface
charge, and targeting agent density,16,18,21,22 and have
enabled rapid screening of the synthesized NPs.22
However, the requirement for specialized microfab-
rication facilities, lack of robustness, and know-how
required to operate the devices creates a barrier for
their utilization in biomedical research laboratories
that often do not have microdevice expertise. More-
over, only a handful of organic solvents are compatible
with conventional polydimethylsiloxane (PDMS) mi-
croﬂuidic systems.23 Their productivity is also typically
low (<0.3 g/h),20,21 which considerably falls short of the
production rates typically required in clinical studies
and industry. While milliﬂuidic systems including con-
ﬁned impinging jet mixer14,24 and multi-inlet vortex
mixer25 have been used for the synthesis of NPs,
specialized micromachining14,24,25 is still required. As
a consequence, the full potential of these devices for
controlled and tunable synthesis of homogeneous NPs
remains unrealized.
Here we demonstrate a simple and versatile coaxial
turbulent jet mixer for synthesizing NPs with high
production rates up to 3 kg/d suitable for in vivo
studies, clinical trials, and industrial-scale production,
while retaining the advantages of homogeneity, re-
producibility, and control over NP properties. More
importantly, the coaxial turbulent jet mixer can be
prepared in half an hour with oﬀ-the-shelf components
and a drill. We demonstrate the versatility of the coaxial
turbulent jet mixer by preparing various types of NPs
including PLGAPEG NPs,16,19,21 lipid vesicles,15,17 iron
oxide NPs,26 polystyrene NPs,24 and siRNA-polyelec-
trolyte (Polyethylenimine: PEI25k,Branched) polyplex
NPs27 by rapid nanoprecipitation and encapsulating
diﬀerent functional agents including anticancer drug,
insulin, ﬂuorescent dyes, and siRNA.
RESULTS
The coaxial turbulent jet mixer consists of coaxial
cylindrical tubes where NP precursors and nonsolvent
are injected through the inner and outer tubes, respec-
tively (Scheme 1). The coaxial turbulent jet mixer is
prepared by inserting a blunt syringe needle into a “T”
tube ﬁtting. Fabrication can be accomplished within
30min without requiring specialized equipment, micro-
fabrication facilities, or specialized skills. In addition,
the coaxial turbulent jet mixer is reusable and the
needle is easily replaceable as needed. While a wide
choice of standard ﬁttings andmaterials can be used to
construct the coaxial turbulent jet mixer, we used PTFE
ﬁttings and tubing that are compatible with a variety of
solvents (Figure 1a). When operated at high ﬂow rates,
the device rapidly mixes the injected solutions by the
formation of a turbulent jet. Because of the rapid
solvent exchange, uniform NPs can be synthesized
by self-assembly of the precursors through a process
known as nanoprecipitation.14,16,19,21
Flow Regimes and Mixing Time Scale. Understanding the
flow behavior and mixing time (τmix) in the coaxial
turbulent jet mixer is important because NP assembly
is strongly influenced by τmix.
14,16 Fluid flow in the
coaxial turbulent jet mixer is defined by two dimen-
sionless parameters:28 flow velocity ratio R = ui/uo, and
the average Reynolds number Re = QD/νA, where ui
and uo are input velocities of inner stream and outer
stream, Q and ν are total flow rate and kinematic
viscosity of the fluid mixture, and D and A are the
diameter and cross-sectional area of outer tube, re-
spectively. The velocity ratio defines how fast the inner
fluid emerges relative to the outer fluid, while the
Reynolds number captures the effect of fluid inertia
relative to viscous forces. In our experiments, flow rates
of inner (Qi) and outer (Qo) fluid streams were con-
trolled by using syringe pumps to vary Re and R
(Supporting Information eq S1 and S2).
Fluid ﬂow and mixing in the device was visualized
using a phenolphthalein solution as the inner ﬂuid,
which becomes colorless upon mixing with the acidic
outer stream (Figure 1b). The ﬂow behavior was
categorized into laminar, transition, vortex and turbu-
lence, and turbulent jet regimes as summarized in the
Scheme1. Schematic illustration of the coaxial turbulent jet
mixer for high-throughput synthesis of NPs. Schematic
illustration of the coaxial turbulent jet mixer with (a) turbu-
lence induced by vortex and (b) turbulence induced by
jetting. The insets show the top view of the turbulent jets (a)
when R = 0.3 and Re = 353, and (b) when R = 10 and Re =
1311, respectively.
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phase diagram (Figure 1c) obtained by analyzing the
ﬂow images (Figure 1b) and videos (Supporting Infor-
mation Video S1). When R < 1, the inner ﬂuid is focused
by the outer ﬂuid and the lower velocity of the inner
ﬂuid stream at the tip of the needle creates recirculat-
ing vortices at low Re. Mixing time is diﬃcult to quantify
in this regime due to entrainment of the ﬂuid in
vortices. In this regime the ﬂow rate of the inner ﬂuid
is very low (Qij 0.01Qo), making it less desirable for NP
synthesis. This regime transitions to vortices and tur-
bulence at higher Re, where amicrovortex is generated
at the tip of the needle and turbulence is developed
downstream. At higher velocity ratios (R J 1), the ﬂow
remains laminar at low Re and a stable stratiﬁed ﬂow is
maintained. Because slow diﬀusional mixing is domi-
nant in the laminar ﬂow regime, the ﬂuid is not
completely mixed. As the Re increases, the ﬂow be-
comes unstable and ﬂuctuates between laminar and
turbulent ﬂows in the transition regime, and ﬁnally
changes to a completely turbulent jet regime that is
desirable for NP synthesis due to rapid mixing and
favorable ﬂow rate ratios (Qi J 0.02 Qo).
In the turbulent jet regime, we estimated the mix-
ing time (τmix) by quantifying the mixing length (L)
where the phenolphthalein color transitioned to
90% of its fully mixed value (Supporting Information
Figure S1). Assuming that the ﬂuid ﬂows at an average
velocity uavg (Supporting Information eq S3), τmix can
be estimated as
τmix ¼ L
uavg
(1)
Operating in turbulent jet regime, the τmix was
tunable in the range of 753 ms by changing Re, with
faster mixing occurring at higher Re (Figure 1d).
To theoretically capture the mixing time scale, we
use the engulfment, deformation, diﬀusion (EDD) tur-
bulent micromixing model.28 In the EDD model, the
unmixed ﬂuid ﬁrst enters turbulent vortices that stir the
ﬂuid at their characteristic frequency, leading to fold-
ing of the ﬂuid into a layered structure. The layers
become thinner with time, and molecular diﬀusion
ﬁnishes the mixing process once the layers are suﬃ-
ciently thin.28 The characteristic time scale (τω) in EDD
turbulent micromixing model is given by
τω  12:7 νÆεæ
 0:5
(2)
Figure 1. Coaxial turbulent jet mixer and analysis of ﬂow regimes andmixing time (τmix). (a) Photograph of coaxial turbulent
jet mixer fabricated from PTFE tee union tube ﬁttings. (b) Schematic illustrations and top views of ﬂuid ﬂow at laminar (R = 1
andRe=237), vortex and turbulence (R=0.3 andRe=353), and turbulent jet (R=10 andRe=1311) regimes. (c) Phasediagram
of jetﬂow regime in termsofR andRe. (d) τmix and (e) dimensionlessmixing timeas a functionofRewhen the coaxial turbulent
jet mixer is operated in turbulent jet regime (i.e., R > 1 and Re is large). Error bars denote ( s.d.
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where ν is the kinematic viscosity and Æεæ is the average
turbulent kinetic energy dissipation rate in the core of
the pipe ﬂow, given by
Æεæ ¼ 0:0668 u
3
avg
Re0:25D
(3)
Normalizing τmix by τω collapses the mixing time to
a value of unity independent of R and Re (Figure 1e),
demonstrating that the mixing time can be estimated
by the EDDmodel when the coaxial turbulent jet mixer
is operated in turbulent jet regime.
Versatile Synthesis of Nanoparticles. The coaxial turbu-
lent jet mixer is a versatile platform that can synthesize
a variety of NPs in a reproducible, controlled, and high-
throughput manner. As proof of concept, we synthe-
sized various NPs that are commonly used for biome-
dical applications, including PLGAPEG NPs, lipid
vesicles, iron oxide NPs, polystyrene NPs, and siRNA/
PEI polyplex NPs (Figure 2).
The size distributions of NPs prepared using coaxial
turbulent jet mixer were narrower and the NPs were
smaller than those prepared by conventional bulk
synthesis methods, as conﬁrmed by both transmission
electron microscope (TEM) images (Figure 2ad and
Supporting Information Figure S2) and dynamic light
scattering (Figure 2eh and Supporting Information
Figure S2). The diameter obtained from dynamic light
scattering is consistent with that obtained from TEM
images in the case of PLGAPEG NPs. Dynamic light
scattering yields a larger diameter for iron oxide NPs
due to dipoledipole interactions,29 but even in this
case TEM analysis reveals a tighter distribution of NP
sizes compared to bulk synthesis (Supporting Informa-
tion Figure S2). The formation of smaller and more
homogeneous NPs occurs because mixing in the coax-
ial turbulent jet mixer is more precisely controlled than
that in bulk synthesis and τmix is smaller than the
characteristic aggregation time scale (τagg). This beha-
vior is consistent with previous reports of nanopreci-
pitation using microﬂuidic devices.14,16,17,19,21 For
example, the polystyrene NPs prepared by coaxial
turbulent jet mixer were more uniform in size distribu-
tion compared to commercially available polystyrene
NPs synthesized by emulsion polymerization method
(Supporting Information Figure S3).
The size of NPs could be controlled reproducibly by
simply changing Re. Operating in turbulent jet regime,
τmix is tunable by changing the Re, with faster mixing at
higher Re (Figure 1d). By simply changing Re, the size of
PLGAPEG NPs could be controlled reproducibly in
Figure 2. NPs prepared using the coaxial turbulent jet mixer. (ad) TEM images, (eh) size distribution by volume fraction,
and (il) eﬀect of Re on the size of (a,e,i) PLGA95k-PEG5k NPs, (b,f,j) lipid vesicles, (c,g,k) iron oxide NPs, and (d,h,l) polystyrene
NPs, respectively. The NP precursors (1) and nonsolvents (2), introduced as inner and outer ﬂuid streams, respectively, are
listed at the top. Error bars denote ( s.d.
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the range of 2560 nm and 50100 nm for PLGA45k-
PEG5k and PLGA95k-PEG5k, respectively, with smaller
NPs being produced at higher Re (Figure 2i). Similar to
the case of PLGAPEGNPs, the size of lipid vesicles, iron
oxide NPs, and polystyrene NPs could be controlled
precisely and reproducibly by simply changing Re, with
smaller size occurring at higher Re (Figure 2jl). The
inﬂuence of τmix on the size of NPs plateaued beyond
a certain Re, suggesting that these NPs had reached the
size corresponding to the limit of rapid mixing.14,21
The coaxial turbulent jet mixer provides an inher-
ently high NP production throughput due to operation
in the turbulent regime with device dimensions in the
millimeter scale, which involves high Re and high ﬂow
rates. Typical Re in the coaxial turbulent jet mixer ranged
from500 to3500 (Figure2il andTable1). Assuming that
all the NP precursors ﬂowing into the device are essen-
tially converted to NPs,20 in case of PLGAPEG NPs we
estimate production rates up to 2.19 g/min (∼3.15 kg/d)
when the coaxial turbulent jet mixer is operated at
high Re (i.e., Re = 3598) and high polymer concentrations
(i.e., 50 mg/mL) (Table 1 and Supporting Information
Video S2). Since the coaxial turbulent jet mixer operates
in continuous mode, we expect that the quality of NPs
will be independent of batch size. To examine the eﬀect
of aggregation of precipitates on NP synthesis, we pre-
pared PLGA95k-PEG5k NPs where the high molecular
weight hydrophobic PLGA block tends to promote
aggregation on the channel walls.19 We observed that
the size distribution of PLGA95k-PEG5k NPswas essentially
identical within standard error for the tens of milligram
synthesis scale and for a few gram scale (Supporting
Information Figure S4), illustrating the robustness of the
coaxial turbulent jet mixer.
Encapsulation of Functional Agents. Polymeric NPs have
received considerable attention in the field of nanome-
dicine as practical platforms for targeted delivery of
therapeutic and diagnostic agents.30,31 NPs loaded with
imaging agents also have the potential for improved
sensitivity and photostability compared to conventional
imaging agents.3,4 The coaxial turbulent jet mixer easily
allows for encapsulation of a variety of functional agents
inNPsby simply including them in theprecursor solution.
We encapsulated docetaxel and insulin in PLGA
PEG NPs as model therapeutic agents for cancer and
diabetes, respectively, by premixing them in the NP
precursor solution (Figure 3ad). In both cases, we did
not observe signiﬁcant changes in the size distribution
of PLGAPEG NPs when themodel therapeutic agents
were encapsulated (Figure 3a,c). Drug loading, deﬁned
as the mass fraction of drug in the NPs, and encapsula-
tion eﬃciency, the fraction of initial drug that is encap-
sulated by the NPs, are important parameters for NP
production. Drug loading obtained by coaxial turbulent
jetmixer was higher than that reported for conventional
bulk methods in literature,7,32 notwithstanding that NPs
synthesized by coaxial turbulent jet mixer are much
smaller compared to conventional bulk methods.
Drug loading and encapsulation eﬃciency obtained
by coaxial turbulent jet mixer were comparable with
those in NPs prepared by microﬂuidic hydrodynamic
ﬂow focusing (Figure 3b).22 Also, encapsulation eﬃ-
ciency of insulin in PLGAPEGNPswas lower compared
to that of docetaxel, because insulin is charged and
more hydrophilic than docetaxel (Figure 3b,d).
The coaxial turbulent jet mixer was also used for
encapsulation of ﬂuorescent dye molecules in lipid
TABLE 1. Total Flow Rate and Production Rate of PLGA
PEG NPs in a Coaxial Turbulent Jet Mixer at Different Rea
Reynolds number 1542 2570 3598
total ﬂow rate 206.25 mL/min 343.75 mL/min 481.25 mL/min
production rate (10 mg/mL) 0.1875 g/min 0.3125 g/min 0.4375 g/min
production rate (50 mg/mL) 0.9375 g/min 1.5625 g/min 2.1875 g/min
a Here, the volumetric ﬂow rate ratio of inner ﬂow to outer ﬂow was ﬁxed at 0.1.
Figure 3. Encapsulation of drugs and ﬂuorescentmolecules
in NPs prepared using the coaxial turbulent jet mixer. (a)
Size distribution and (b) drug loading and encapsulation
eﬃciency of PLGA45k-PEG5k NPs with docetaxel as a model
therapeutic agent. (c) Size distribution and (d) drug loading
and encapsulation eﬃciency of PLGA45k-PEG5k NPs with
insulin as a model therapeutic agent. (e) Size distribution
of lipid vesicles without and with DiIC18 dye. (f) Photograph
and ﬂuorescence microscope image of lipid vesicles with
DiIC18 dye. (g) Size distribution of polystyrene NPs without
and with perylene dye. (h) Photograph and ﬂuorescence
microscope image of polystyrene NPs with perylene dye.
Error bars denote ( s.d.
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vesicles and polystyrene NPs as model imaging agents
(Figure 3eh). When lipid vesicles were loaded with
ﬂuorescent dye molecules (DiIC18), the average size of
NPs increased slightly (Figure 3e) because DiIC18 dye is
a membrane intercalating dye.15 On the other hand,
the average size of polystyrene NPs increased signiﬁ-
cantly with encapsulation of ﬂuorescent dyemolecules
(perylene) (Figure 3g), presumably because the hydro-
phobicity of perylene aﬀects the NP assembly. Encap-
sulation of these ﬂuorescent dye molecules was
conﬁrmed visually and by ﬂuorescence microscopy
(Figure 3f,h).
In Vitro Gene Knockdown by siRNA/PEI Polyplex NPs. The
coaxial turbulent jet mixer can overcome the issues of
batch-to-batch reproducibility that are often a consid-
erable challenge for scale-up of NP synthesis from
the laboratory to clinical and industrial production.1,8,9
We illustrate this with the example of siRNA, which
has emerged as one of the strongest candidates for
RNA interference therapy.33 However, use of siRNA as
a practical therapeutic agent is challenging due to its
susceptibility to degradation by nucleases present in
the body fluids, its relatively high molecular weight,
and its anionic charge that limits cellular uptake and
transport to the cytosol.34 These challenges can be
overcome by employing delivery systems or carriers.
One of the promising approaches is by condensing
the siRNA into a compact size by using counterion
polyelectrolyte (e.g., PEI, chitosan, etc.) to protect the
activity of siRNA, to screen the negative charge for
enhancement of the cellular accumulation, and to
ensure endosomal escape of the siRNA for effective
RNA interference.27,35,36
Similar to other polyelectrolyte interactions, siRNA/
polycation polyplex NP formulations prepared by bulk
synthesis method have limited uniformity, batch-to-
batch reproducibility, and scalability. In case of the
conventional bulk synthesis method, scale-up for the
synthesis of siRNA/polycation polyplex NPs is a con-
undrum because the physicochemical properties of
NPs are signiﬁcantly altered as the batch size is in-
creased for scale-up, as illustrated by the observed
diﬀerences in the size distributions of polyplex NPs
prepared in diﬀerent batch sizes using the conven-
tional bulk synthesis method (Figure 4a). In contrast,
the coaxial turbulent jet mixer can synthesize siRNA/
PEI polyplex NPs in a continuous and high-throughput
manner, resulting in smaller NPs with narrower size
distributions compared to those prepared by bulk
synthesis (Figure 4a). The properties of NPs synthesized
using the coaxial turbulent jet mixer are independent
of the batch size (i.e., amount of NPs synthesized)
because the conditions for NP formation are identical
and independent of the batch size for all NPs produced.
The transfection ability and resulting gene knock-
down of siRNA/PEI polyplex NPs (molar ratio 1:3) were
studied in vitro by using dual-luciferase (ﬁreﬂy and
renilla) expressing HeLa cell line. In case of siRNA/PEI
polyplex NPs synthesized by coaxial turbulent jet
mixer, the luciferase expression was reduced by 50
and 60% at eﬀective siRNA concentrations of 20 and
50 μM, respectively (Figure 4b). In case of commercially
available transfection agent Lipofectamine 2000, how-
ever, the luciferase expression was reduced by only
5% at a siRNA concentration of 20 μM, but was brought
down by 60% at siRNA concentration of 50 μM
(Figure 4b). This result illustrates the utility of the
coaxial turbulent jet mixer to ensure batch-to-batch
reproducibility of siRNA/PEI polyplex NPs while main-
taining the eﬀectiveness for gene knockdown.
DISCUSSION
The application of NPs synthesized by microﬂuidic
platforms to large-animal in vivo and clinical studies
has been challenging due to the intrinsic problem of
low production rates.1,2 A few milliﬂuidic mixers have
Figure 4. Reproducible preparation and eﬀectiveness of
siRNA/PEI polyplex NPs using the coaxial turbulent jet
mixer. (a) Size distribution of siRNA/PEI polyplex NPs pre-
pared by coaxial turbulent jet mixer, compared to bulk
synthesis with diﬀerent batch sizes (2 and 40mL) that show
variability in NP size. Inset shows the TEM image of siRNA/
PEI polyplexNPs prepared by coaxial turbulent jetmixer. (b)
Luciferase expression (%) in HeLa cells expressing both
ﬁreﬂy and renilla luciferase, treated with NPs carrying GL3
siRNA, at various eﬀective siRNA concentrations (i.e., 20 and
50 μM) relative to scrambled siRNA, used as control. All
results correspond to 2 days post-transfection, and are
compared to commercially available transfection reagent
Lipofectamine 2000. Cells treatedwith free siRNA had 100%
luciferase expression. Error bars denote ( s.d.
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been developed to overcome this drawback; however,
they are not widely adopted in biomedical laboratories
because fabrication of the milliﬂuidic systems requires
specialized micromachining.14,24,25
We developed a simple and versatile coaxial turbu-
lent jet mixer for synthesis of various types of NPs. The
coaxial turbulent jet mixer can be prepared within
30 min without any specialized equipment, micro-
fabrication facilities, or specialized skills. In addition, the
coaxial turbulent jet mixer can be made from standard
ﬁttings and materials that exhibit good solvent resis-
tance. The ﬂuid ﬂow and mixing process does not
require very precise alignment of the inner and outer
tubes. To ensure that the inner tube is coaxially aligned
with the outer tube (typically within 0.5 mm of the axis
of the outer tube) we used metal syringe needle as the
inner tube and ﬁxed the outer ﬂexible tubing on a rigid
plate. The ﬂow behavior in the coaxial turbulent jet
mixer was captured as images and videos by system-
atically changing R and Re and summarized as phase
diagram (Figure 1c). If there are signiﬁcant diﬀerences
in relative densities and viscosities of the inner and
outer ﬂuid, the inner stream can touch the inner wall of
outer tube in the laminar ﬂow regime. In the vortex and
turbulence regime and turbulent jet regime, on the
other hand, this eﬀect is negligible because of fast
lateral ﬂow velocity of ﬂuids. Since the coaxial turbu-
lent jet mixer was operated in the turbulent jet regime
for NP synthesis, the eﬀect of small diﬀerences in
relative densities and viscosities on NP synthesis is
negligible. By ﬂowing NP precursor and nonsolvent
through inner and outer tubes, respectively, we can ﬁx
the ratio of NP precursor and nonsolvent, which is one
of the important parameters that determines the NP
size distribution. As proof of concept, we demon-
strated the synthesis of PLGAPEG NPs, lipid vesicles,
iron oxide NPs, polystyrene NPs, and siRNA/PEI poly-
plex NPs, which are themajor types of NPs widely used
in biomedical applications. In addition, we demon-
strated single-step encapsulation of various functional
agents including anticancer drug, insulin, ﬂuorescent
dyes, and siRNA. The synthesized NPs could be easily
recovered and separated by using ultraﬁltration or freeze-
drymethod.Weexpect that thismixer design canbeused
to synthesize other types of NPs and microparticles.
The coaxial turbulent jet mixer can resolve the
production rate issuewithout compromising on the con-
trollability and reproducibility oﬀered by microﬂuidic
platforms. NP precursors are introduced through in-
ner stream that is surrounded by the outer stream,
mitigating direct precipitation on the surfaces. More-
over, since the high ﬂow speed of the ﬂuid washes
away all precipitates toward collection bath, there is no
buildup of precipitate onto the channel wall even after
operation for a long time (Supporting Information
Figure S4). The coaxial turbulent jet mixer could
achieve a production rate up to 2.19 g/min, which is
equivalent to 3.15 kg/d and 1.15 ton/yr. Considering
that the production rates typically required for drug
delivery applications in clinical studies and industrial-
scale production of NPs are on the order of 0.1 and
1 kg/d, respectively, it is noteworthy that a single coaxial
turbulent jet mixer can meet both requirements. In
addition, controlled and rapid mixing in the coaxial
turbulent jet mixer leads to more homogeneous and
smaller NPs compared to those synthesized by con-
ventional bulk synthesis methods. Since smaller NPs
can penetrate more deeply into solid tumors,37,38 the
coaxial turbulent jet mixer has the potential to synthe-
size NPs with better drug delivery performance com-
pared to conventional bulk methods. As a proof of
concept, siRNA/PEI polyplex NPs were formulated
using the coaxial mixer device, which could knock
down the target gene more eﬀectively as compared
to a commercially available transfection agent at lower
siRNA dose (Figure 4b). The coaxial turbulent jet mixer
also allows for reproducible synthesis of NPs from
quantities suitable for in vitro assays (requiring only a
few seconds for synthesis) all the way up to industrial-
scale production. One can also envision directly jetting
the inner ﬂuid into a stirred beaker for rapid mixing to
provide better control over conventional nanoprecipi-
tation in bulk, although the nanoprecipitation condi-
tions will vary as the composition of the solution in the
beaker changeswith time. The ability to synthesize NPs
at quantities over the entire range from initial bench-
top screening all the way to manufacture obviates
many of the issues regarding reoptimization of NP
synthesis processes to account for changes in NP
properties that usually occur with scale-up.
CONCLUSION
We reported a simple and versatile coaxial turbulent
jet mixer that can synthesize various types of NPs with
high production rates up to 3.15 kg/d. The coaxial
turbulent jet mixer could be fabricated within 30 min
without requiring specialized equipment, microfabri-
cation facilities, or specialized skills, making it easily
accessible to nanomedicine researchers. We character-
ized the ﬂuidic behavior of this device to identify the
turbulent jet regime where eﬀective mixing is ob-
tained, which occurs at Reynolds numbers above 500
and ﬂow velocity ratios greater than 1. We further
established the versatility of this platform by reprodu-
cibly synthesizing PLGAPEG NPs, lipid vesicles, iron
oxide NPs, polystyrene NPs, and siRNA/PEI polyplex
NPs. We also encapsulated diﬀerent functional agents
including anticancer drug, insulin, ﬂuorescent dyes,
and siRNA. As a proof of concept, we performed in vitro
gene knockdown study using siRNA/PEI polyplex NPs
rapidly synthesized by the coaxial turbulent jet mixer,
which are not easily synthesized in a reproducible
manner by conventional methods. In summary, the
coaxial turbulent jet mixer can be used as a versatile
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platform for reproducible and controlled synthesis of
NPs with high throughput suitable for large animal
in vivo studies, clinical trials, and industrial-scale pro-
duction. This technology has the potential to expedite
the development and translation of new nanomedicines
to the clinic for diagnostic and therapeutic applications,
and to also impact bulk synthesis of NPs for a variety of
other nonmedical applications.
METHODS
Fabrication of Coaxial Turbulent Jet Mixer. Tee union tube fittings
made of clear polycarbonate (McMaster-Carr) or PTFE
(Plasmatech Co.) were used for fabrication. A hole was drilled
using a 0.025 in. diameter drill bit (#72, Drill bit city) and a 23 G
blunt needle (337 μm I.D. and 641.4 μm O.D., Strategic applica-
tions Inc.) was inserted through the drilled hole and fixed by
optical adhesive (NOA81, Norland products) and cured under
UV light. Silastic tubing (VWR scientific products) or PTFE tubing
(Plasmatech Co.) with inner diameters D = 3.175 mm were
connected to the tee union tube fitting using a connector and
adaptor (IDEX Health & Science).
Characterization of Mixing in the Coaxial Turbulent Jet Mixer. The
device made from clear polycarbonate and transparent silastic
tubes was used for the imaging and characterization of flow
behavior in the coaxial turbulent jet mixer, since PTFE tee union
and Teflon tubes are not transparent (Figure 1a,b). The flow rates
were controlledby syringepumps (HarvardApparatus).Mixingof
the inner and outer streams was visualized using phenolphtha-
lein (Sigma-Aldrich). Because phenolphthalein is insoluble in
water, 0.1 N sodiumhydroxide (Sigma-Aldrich) in waterethanol
mixture (1:2 in volume ratio) with 1% w/v phenolphthalein was
used as the pink colored basic inner solution. The composition
of outer solution was 0.1 N hydrogen chloride (Sigma-Aldrich)
in waterethanol mixture (1:2 in volume ratio). To match the
densities of inner fluid and outer fluid, same composition of
waterethanol mixture was used to prepare basic inner solution
and acidic outer solution. As a result, the vertical buoyancy-
driven drift of the inner fluid stream was negligible (Figure 1b).
To estimate the Re, kinematic viscosity (ν) of waterethanol
mixture was calculated by using the previously reported values
of dynamic viscosity (μ) and density (F) in waterethanol
mixtures.39 Enhanced aluminum-coated right-angle prismmirror
(Edmund optics, Inc.) was placed adjacent to the coaxial turbu-
lent jetmixer to capture top and side views simultaneously, while
the images and videos were taken from above the coaxial
turbulent jet mixer. The flow in the coaxial turbulent jet mixer
was captured as images and videos by systematically varying R
and Re. Lwas determinedby analyzing images in ImageJ, defined
as the length at which the gray value of the green channel split
from the image was 90% of the intensity difference between the
completely mixed flow far downstream along the centerline and
the tip of the inner syringe needle (Supporting Information
Figure S1). In cases where the flow was still unmixed at the edge
of right angle prism mirror (i.e., in 75 mm), L was not estimated.
Preparation of PLGAPEG NPs. PLGA45k-PEG5k and PLGA95k-
PEG5k (Boehringer Ingelheim GmbH) was dissolved in acetoni-
trile (ACN, Sigma-Aldrich) at concentrations of 10 or 50 mg/mL.
For the drug loading test, docetaxel (LC laboratories) and
human recombinant insulin (Sigma-Aldrich) were used as
model therapeutic agents. The PLGAPEG precursor in ACN
and deionized water were used as inner and outer stream,
respectively. To make insulin loaded PLGAPEG NPs, dimethyl
sulfoxide (DMSO, Sigma-Aldrich) was used as organic solvent,
because insulin is not soluble in ACN. During the NP synthesis,
the flow rates were controlled by syringe pumps (Harvard
Apparatus). To estimate the Re, ν of waterACN mixture and
waterDMSO mixture were calculated by using the previously
reported values of μ and F in waterACN mixtures and water
DMSO mixtures, respectively.40,41 The output stream from the
coaxial turbulent jetmixerwas collected in abeaker. The resulting
NP suspension was purified by ultrafiltration using Amicon
Ultracel 100 K membrane filters. In case of bulk synthesis, 100 μL
of polymeric precursor solutionwasmixed dropwisewith 1mL of
water for about 2 h under magnetic stirring.
Preparation of Lipid Vesicles. Dimyristoylphosphatidylcholine
(DMPC, Avanti Polar Lipids, Inc.), cholesterol (Avanti Polar Lipids,
Inc.), and dihexadecyl phosphate (DCP, Sigma-Aldrich) were
dissolved in a molar ratio of 5:4:1 in chloroform (Sigma-Aldrich).
The chloroform was removed by evaporation under a stream of
nitrogen gas at 30 C. The glass vial with a dry lipid blend was
stored in a desiccator for 24 h to remove residual chloroform.
The lipid blend was dissolved in isopropyl alcohol (IPA) at
concentration of 5mM. Tomake fluorescent lipid vesicles, 1 wt%
of 1,10-dioctadecyl-3,3,30 ,30-tetramethylindocarbocyanine per-
chlorate (DiIC18, Sigma-Aldrich) with respect to the total weight
of the lipid blend was added to the lipid blend in the IPA
solution. The lipid blend in IPA solution and phosphate buffered
saline (PBS) were used as inner and outer streams, respectively.
To estimate the Re, ν of waterIPA mixture was calculated by
using the previously reported values of μ and F in waterIPA
mixtures.42 In case of bulk synthesis, 100 μL of lipid blend in IPA
solution was mixed dropwise with 1 mL of PBS for about 2 h
under magnetic stirring.
Preparation of Iron Oxide NPs. Iron(II) chloride tetrahydrate and
iron(III) chloride (Sigma-Aldrich) was dissolved in 1 N hydro-
chloric acid (Sigma-Aldrich) at concentration of 10 mM in a
molar ratio Fe (II)/Fe (III) of 1:1. The iron oxide precursor in
hydrochloric acid and alkaline solution of tetramethylammo-
nium hydroxide (TMAOH, Sigma-Aldrich) at concentration of
172 mM were used as inner and outer streams, respectively. In
case of bulk synthesis, 100 μL of iron oxide precursor in
hydrochloric acid solution were mixed dropwise with 1 mL of
TMAOH for about 2 h under magnetic stirring.
Preparation of Polystyrene NPs. Polystyrene (MW 35000, Sigma-
Aldrich) was dissolved in tetrahydrofuran (THF, Sigma-Aldrich)
at a concentration of 1mg/mL. Tomake fluorescent polystyrene
NPs, 10 wt % of perylene (Sigma-Aldrich) to the total weight of
polystyrene was added to the polystyrene in THF solution. The
polystyrene precursor in THF and deionized water were used as
inner and outer streams, respectively. To estimate the Re, ν of
waterTHF mixture was calculated by using the previously
reported values of μ and F in waterTHF mixtures.43 In case
of bulk synthesis, 100 μL of polystyrene precursor solution was
mixed dropwise with 1 mL of water for about 2 h under
magnetic stirring.
Preparation of siRNA/PEI Polyplex NPs. The siRNA/PEI polyplex
NPs were prepared by mixing aqueous solution of siRNA
(Luciferase (GL3): sequence 50-CUU ACG CUG AGU ACU UCG
AdTdT-30 (sense) and 50-UCG AAG UAC UCA GCG UAA GdTdT-30
(antisense)) and polyethylenimine (PEI25k,Branched) at varying
molar ratios (siRNA:PEI = 1:1 to 1:4). The aqueous siRNA solution
and aqueous PEI solution were used as inner and outer streams,
respectively. In case of bulk synthesis, 4 mL of aqueous siRNA
solution and 40 mL of aqueous PEI solution was mixed by
vortexing at 1500 rpm, at different concentrations so as to keep
the desired molar ratios of siRNA and PEI as described above.
The synthesized siRNA/PEI polyplex NPs were lyophilized and
stored at 20 C until use.
Characterization of NPs. The size distributions by volume frac-
tion of the synthesized NPs and polystyrene microspheres
(99 nm, Bangs laboratories, Inc.) were measured using dynamic
light scattering with Zetasizer Nano ZS (Malvern Instruments,
Ltd.). The synthesized NPs were imaged by TEM (JEOL 200CX).
For TEM imaging, PLGAPEG NPs and lipid vesicles were
stained by uranyl acetate (Electron Microscopy Sciences).
Docetaxel loading in the PLGAPEG NPs were measured by
HPLC (Agilent Technologies, 1100 Series) using established
procedures.32 Insulin loading in the PLGAPEGNPswasmeasured
by a protein bicinchoninic acid (BCA) assay (Lamda Biotech).
Fluorescence images of lipid vesicles and polystyrene NPs were
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acquired using an epi-fluorescencemicroscope (EclipseTE 2000-U,
Nikon). The typical sample volume for characterizationwas 15 and
1.1 mL for coaxial turbulent jet mixer and bulk synthesis method,
respectively.
In Vitro Transfection. All the in vitro transfection experiments
were performed in quadruplicate. Dual-Luciferase (Luc) HeLa
cells were grown and then seeded in 96-well plates at a density
of 10000 cells/well 18 h before transfection. The cells were
incubated for 24 h with various amounts of siRNA/PEI poly-
plex NPs in media without FBS. For all the NP treatments
encapsulating GL3 siRNA, scrambled siRNA/PEI polyplex NP was
usedasnegative control. Lipo2000/siRNAcomplexwas formulated
following the manufacturer's protocol (Invitrogen) and was used
as a positive control for transfection. After the incubation period,
the cells werewashedwith growthmedia and allowed to grow for
a period of 24 h. The HeLa cells were then analyzed for expression
of firefly and renilla luciferase signals by using the Dual-Glo
Luciferase Assay System (Promega). The luminescence intensity
was measured using a microplate reader (BioTek).
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